Contract
Material Handler
Posted on 8/19/2026
Personalis
201-500 employees
Specialized cancer genomics sequencing and analysis
Compensation Overview
$21 - $27/hr
Fremont, CA, USA
In Person
 Operations & Logistics (1) |
|---|
Get referred to Personalis
See people who can refer or advise you
- A high school diploma and 1–4 years of relevant experience working in an operations environment are required.
- Experience in a Good Manufacturing Practice, Food and Drug Administration, or International Organization for Standardization 13485 regulated environment is highly desired.
- A valid International Air Transport Association Dangerous Goods certification is highly desired.
- Experience processing and monitoring inbound and outbound shipments is highly desired.
- Computer literacy and the ability to work within quality systems, QAD, or other enterprise resource planning systems are required.
- The ability to work effectively in a team environment and maintain attention to detail is required.
- Receive, unpack, and check materials against purchase orders for damage, accuracy, and completeness.
- Label and put away incoming materials.
- Rotate inventory based on first-in, first-out procedures and expiration dates.
- Perform routine cycle counts.
- Lift heavy items weighing up to 50 pounds.
- Enter data and maintain records in compliance with regulatory requirements, including Good Manufacturing Practice and quality systems.
- Maintain laboratory Kanbans.
- Maintain an organized, safe, and clean work environment.
- Collaborate with other departments to ensure the warehouse aligns with future International Organization for Standardization and Food and Drug Administration requirements.
- Process weekly UN1845 and UN3373 shipments.
- Experience in a Good Manufacturing Practice, Food and Drug Administration, or International Organization for Standardization 13485 regulated environment.
- A valid International Air Transport Association Dangerous Goods certification.
- Experience processing and monitoring inbound and outbound shipments.
Personalis provides cancer genomics services, including sequencing and data analysis for pharma, academia, and clinicians. Its NeXT Platform analyzes a tissue sample to generate molecular data across about 20,000 genes, covering tumor and immune features. A key product, NeXT Personal, detects minimal residual disease and cancer recurrence by measuring circulating tumor DNA to guide care. The company aims to enable precise, data-driven cancer treatment and monitoring through integrated sequencing, analysis, and biomarker discovery.
Company Size
201-500
Company Stage
IPO
Headquarters
Menlo Park, California
Founded
2011
Get referred to Personalis
See people who can refer or advise you
Simplify's Take
What believers are saying
- Tempus agreed July 20, 2026 to buy Personalis for $16.25 a share.
- June 2026 CE-IVD marking opened NeXT Personal specimen kits to EU and Great Britain trials.
- Medicare expanded NeXT Personal coverage through May 20, 2026, including breast-cancer treatment monitoring.
What critics are saying
- Shareholders still need approval; antitrust or financing issues can delay Tempus closing into 2027.
- MRD reimbursement remains indication-by-indication; CMS reversals would crush Personalis' 2026 clinical revenue growth.
- If Tempus walks, Personalis faces shrinking standalone scale, persistent losses, and takeover-whiplash attrition.
What makes Personalis unique
- NeXT Personal detects ctDNA at single-digit ppm, beating less-sensitive MRD rivals in 2026 data.
- Personalis pairs tumor-informed MRD with whole-genome profiling, spanning recurrence monitoring and biomarker discovery.
- Stanford founders and Tempus' 2026 acquisition give Personalis unusually deep oncology and commercialization access.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Employee Stock Purchase Plan
Tuition Reimbursement
Paid Vacation
Paid Sick Leave
Commuter Benefits
Wellness Program
Gym Membership
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 1%2 year growth
↑ 0%Tempus to acquire Personalis for $1.5B, deepening bet on cancer diagnostics. Tempus AI has agreed to acquire Personalis, a Fremont, California-based maker of molecular residual disease (MRD) tests, for $1.5 billion, the companies announced Monday. Under the deal, Tempus will pay $16.25 per share for Personalis' outstanding stock - about a 6% premium to Friday's closing price - with the option to settle up to half the consideration in cash. The transaction is expected to close in late 2026 or early 2027, pending shareholder and regulatory approval. The acquisition builds on a commercial partnership the two companies formed in 2023 to co-market Personalis' MRD test, which screens for cancer recurrence. Tempus CEO Eric Lefkofsky told investors Monday that an outright purchase was considered back then too, but Tempus opted for the partnership route since Personalis still needed years of investment before its test could scale. Personalis has since secured Medicare coverage for three indications, with more expected. The combination pairs two different MRD approaches: Personalis' tumor-informed test, which draws on a patient's own tumor sample, and Tempus' tumor-naive offering. Lefkofsky said volume has "shifted pretty dramatically" toward tumor-informed testing in recent quarters, though Tempus still plans to invest in its tumor-naive line. On the numbers, Personalis reported preliminary Q2 revenue of $22.4 million and delivered 10,384 tests, up 33% from Q1. Tempus, meanwhile, sold roughly 9,000 Personalis tests in Q2, up from 5,500 in Q1. The deal lands amid a broader industry rush into blood-based cancer diagnostics: Abbott closed its $21 billion Exact Sciences acquisition in March, Guardant's Shield colon cancer blood test recently won UnitedHealth coverage, and Freenome just reported strong pivotal-study results for its own colorectal screening test.
Tempus AI's $1.5B Personalis acquisition: why MRD is becoming a strategic battleground in cancer care. Tempus AI's planned $1.5 billion acquisition of Personalis is more than a conventional diagnostics deal. It signals a broader shift in oncology: blood-based cancer testing is moving from an emerging technology category to a strategic platform for diagnosis, treatment selection, recurrence detection, and long-term monitoring. The deal comes amid accelerating industry momentum: - Abbott recently completed its $21 billion acquisition of Exact Sciences - Guardant's blood-based colorectal cancer test gained UnitedHealthcare coverage - Freenome advanced its pivotal study for blood-based colorectal cancer screening The strategic logic behind the Personalis acquisition is clear. - Building an end-to-end oncology platform Personalis' molecular residual disease (MRD) test could strengthen Tempus' capabilities across the cancer care journey, from diagnosis to recurrence monitoring. - Combining complementary technologies Personalis brings a tumor-informed MRD assay, while Tempus has developed a tumor-naive approach. The combination provides broader coverage across evolving clinical use cases. - Acquiring at the right point in market maturity Tempus initially partnered with Personalis in 2023 rather than acquiring the company, allowing the MRD platform time to develop clinical traction and reimbursement coverage. That strategy now appears increasingly validated. Personalis has secured Medicare coverage in three indications, while preliminary second-quarter revenue reached $22.4 million. Test volumes also rose 33% sequentially to 10,384. The larger takeaway? In oncology diagnostics, the next competitive advantage may not come from a single test; but from owning the data, clinical evidence, reimbursement pathways, and longitudinal patient insights that connect testing to treatment decisions. Tempus' move suggests the future of cancer diagnostics will be increasingly integrated, data-driven, and centered on continuous monitoring - not one-time diagnosis. #TempusAI #Personalis #LiquidBiopsy #MRD #Oncology #CancerDiagnostics #MedTech #PrecisionMedicine #Diagnostics #HealthcareInnovation #MolecularDiagnostics #Biotechnology
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that it has en...
Tempus AI has agreed to acquire Personalis for $16.25 per share, representing a total enterprise value of $1.5 billion, net of Tempus' existing ownership. The acquisition will expand Tempus' capabilities in minimal residual disease and enhance its ability to support patients throughout their cancer journey. Under the terms, Personalis shareholders will receive $16.25 per share, a 6% premium to Friday's closing price and 28% premium to the 30-day volume-weighted average price. The transaction will be structured as 100% stock, with Tempus having the option to pay up to 50% in cash. The deal builds on the companies' existing partnership from November 2023. It combines Tempus' multimodal data platform and AI capabilities with Personalis' tumour-informed MRD technology. The transaction is expected to close in late 2026 or early 2027, subject to shareholder and regulatory approvals.
Tempus to acquire Personalis for $1.5B. Shares of both companies plunged following the announcement, which comes less than a year after Tempus acquired digital-pathology company Paige for $81.25 million. By Eve Bender | July 20, 2026 | 3:03 PM AI data company Tempus AI announced it will acquire cancer genomics company Personalis in a transaction valued at approximately $1.5 billion. The acquisition will integrate Personalis' molecular residual disease testing into Tempus' AI precision oncology platform. Under the definitive agreement, Personalis shareholders will receive $16.25 per share, primarily in Tempus stock. Tempus has the option to pay up to 50% of the consideration in cash. The purchase price represents a roughly 6% premium over Personalis' closing price Friday and a 28% premium over its unaffected 30-day volume-weighted average share price, according to the companies. Tempus already owns approximately 12.5% of Personalis. Shares of both companies fell sharply after the announcement. Tempus AI stock was down nearly 9%, while Personalis shares declined about 12% during Monday morning trading. The transaction is expected to close in late 2026 or early 2027, subject to approval by Personalis shareholders, regulatory clearances and other customary closing conditions. The boards of both companies unanimously approved the deal. Personalis' NeXT Personal platform uses whole-genome sequencing to create a personalized genetic signature of a patient's tumor. Blood tests can then identify circulating tumor DNA that may remain after treatment or return in the future. Molecular residual disease (MRD) testing is intended to detect traces of cancer that may be too small to appear on imaging. "MRD is a large and rapidly growing market with the potential to truly transform how cancer patients are monitored, helping clinicians make faster and more informed decisions when cancer recurs," Eric Lefkofsky, CEO of Tempus, said in a statement. Tempus said integrating the technology into its platform could help the company support patients from diagnosis and treatment selection through recurrence monitoring. The acquisition builds on a relationship the companies established in 2023. Under their agreement, Tempus began offering Personalis' tumor-informed MRD testing to pharmaceutical and biotechnology customers. The companies expanded the partnership in 2025, allowing Tempus to market NeXT Personal Dx for colorectal cancer. "We believe this transaction represents an exciting next chapter for Personalis," Chris Hall, CEO of Personalis, said in a statement. "Combining with Tempus gives us the scale, complementary capabilities and resources to accelerate innovation and deliver even greater value to patients, clinicians and biopharma partners." THE LARGER TREND In August 2025, Tempus acquired Paige, an AI-enabled diagnostic platform for oncologists and pathologists, for $81.25 million. The acquisition expanded Tempus' presence in digital pathology and added Paige's collection of digitized pathology slides, clinical reports and genomic data to its platform. Earlier that year, the company launched an AI-enabled personal health concierge app that allows patients to aggregate medical records and data from connected health devices. Tempus has also formed oncology-focused collaborations with pharmaceutical companies. The company partnered with Pfizer to apply AI and machine learning to cancer drug discovery, clinical-trial matching and companion diagnostics.